Table 2:
Decision to select point-of-care (POC) versus standard phlebotomy HCV antibody testing among clients in a mobile medical clinic (MMC) in New Haven, Connecticut, 2012-2013 (N=438).
| Correlates | Total observed | HCV Testing Strategy Selected N=438 |
Pearson Chi-squared p-value | |||
|---|---|---|---|---|---|---|
| Point-of-Care N=209 |
Standard N=229 |
|||||
| N observed (95% CI) | N imputed (%) | N observed (95% CI) | N imputed (%) | |||
| HCV test | ||||||
| Positive | 27 | 16 | - | 11 | - | 0.219 |
| (8,24) | 7.7% | (5,17) | 4.8% | |||
| Negative | 411 | 193 | 193 | 218 | 218 | 0.219 |
| (185,201) | 92.3% | (212,224) | 95.2% | |||
| Mean age [S.D.] | 35.6 | 36.0 | 36.0 | 35.3 | 35.3 | 0.497 |
| (34.2,37.7) | [12.2] | (33.9,36.8) | [11.0] | |||
| Baby boomer generation | 57 | 32 | 36 | 25 | 38 | 0.857 |
| (25,47) | 17.2% | (26,49) | 16.6% | |||
| Gender | ||||||
| Male | 242 | 113 | 119 | 129 | 137 | 0.604 |
| (105,134) | 56.9% | (121,152) | 59.8% | |||
| Female | 173 | 86 | 90 | 87 | 92 | 0.604 |
| (75,104) | 43.0% | (77,108) | 40.2% | |||
| Race | ||||||
| Non-Hispanic White | 89 | 58 | 62 | 31 | 36 | <0.01 |
| (48,75) | 29.7% | (24,48) | 15.7% | |||
| Non-Hispanic Black | 175 | 87 | 92 | 88 | 103 | 0.853 |
| (78,106) | 44.0% | (87,119) | 45.0% | |||
| Hispanic | 126 | 50 | 53 | 76 | 89 | <0.01 |
| (40,65) | 25.4% | (73,106) | 38.9% | |||
| Foreign-born | 147 | 49 | 54 | 98 | 130 | <0.01 |
| (40,67) | 25.8% | (112,147) | 56.8% | |||
| Unstable housing | 63 | 18 | 68 | 45 | 76 | 0.244 |
| (39,98) | 32.5% | (59,93) | 33.2% | |||
| No health Insurance | 112 | 31 | 112 | 81 | 123 | 0.198 |
| (78,147) | 53.6% | (103,142) | 53.7% | |||
| Not in a stable relationship | 173 | 50 | 183 | 123 | 200 | 0.887 |
| (163,203) | 87.7% | (188,211) | 87.3% | |||
| Prior diagnosis of HCV | 23 | 12 | 12 | 11 | 14 | 0.351 |
| (5,19) | 5.7% | (5,22) | 6.1% | |||
| Prior diagnosis of STI | 105 | 23 | 95 | 82 | 133 | 0.660 |
| (0,205) | 45.5% | (103,162) | 58.1% | |||
| Injection drug history (PWID) | 76 | 47 | 53 | 29 | 44 | 0.187 |
| (40,66) | 25.4% | (30,57) | 19.2% | |||
| Heroin | 39 | 16 | 56 | 23 | 52 | 0.43 |
| (39,73) | 26.8% | (37,67) | 22.7% | |||
| Cocaine | 70 | 22 | 78 | 48 | 86 | 0.954 |
| (51,104) | 37.2% | (68,104) | 37.6% | |||
| Use of NSEP | 7 | 4 | 16 | 3 | 12 | 0.623 |
| (0,39) | 7.7% | (0,24) | 5.2% | |||
| Crack cocaine use | 50 | 21 | 63 | 29 | 55 | 0.453 |
| (34,91) | 30.1% | (38,72) | 24.0% | |||
| Non-injection drug use | 106 | 23 | 95 | 83 | 122 | 0.305 |
| (72,118) | 45.5% | (103,141) | 53.3% | |||
| History of incarceration | 106 | 30 | 119 | 76 | 127 | 0.779 |
| (90,149) | 57.0% | (107,146) | 55.5% | |||
| History of interpersonal violence | 44 | 20 | 66 | 24 | 42 | 0.085 |
| (39,94) | 31.6% | (28,56) | 18.3% | |||
| Occupational exposure to blood | 9 | 8 | 11 | 1 | 8 | 0.674 |
| (3,19) | 5.1% | (0,25) | 3.5% | |||
| Household known HCV+ individual | 20 | 17 | 39 | 3 | 50 | 0.972 |
| (0,82) | 18.6% | (0,146) | 21.8% | |||
| MSM | 20 | 12 | 13 | 8 | 11 | 0.460 |
| (6,20) | 6.3% | (3,19) | 4.8% | |||
| Tattoo history | 112 | 90 | 121 | 22 | 102 | 0.197 |
| (104,139) | 57.9% | (0,160) | 44.5% | |||
| Lifetime sexual partners > 15 | 133 | 106 | 115 | 27 | 40 | <0.01 |
| (100,129) | 55.0% | (26,54) | 17.5% | |||
Note: Nimputed is sample size based on the frequency estimate from multiple imputation procedure. Cocaine and heroin numbers reflect total users of either intravenous, oral, or inhaled routes.
LEGEND: HCV: Hepatitis C Virus; HCV Ab: Hepatitis C Antibody; STI: Sexually Transmitted Infection PWID: People Who Inject Drugs; NSEP: Needle Syringe Exchange Program; MSM: Men Who Have Sex with Men.